神经内分泌前列腺癌发生发展中的分子事件。
Molecular events in neuroendocrine prostate cancer development.
机构信息
Vancouver Prostate Centre, Vancouver, BC, Canada.
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
出版信息
Nat Rev Urol. 2021 Oct;18(10):581-596. doi: 10.1038/s41585-021-00490-0. Epub 2021 Jul 21.
Abstract
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a subject of debate. The survival of patients with NEPC is poor, and few effective treatment options are available. To improve clinical outcomes, understanding of the biology and molecular mechanisms regulating NEPC development is crucial. Various NEPC molecular drivers make temporal contributions during NEPC development, and despite the limited treatment options available, several novel targeted therapeutics are currently under research.
摘要
神经内分泌前列腺癌（NEPC）是一种致命的前列腺癌亚型。NEPC 很少从头发生成，这种疾病主要是在药物诱导的雄激素受体信号抑制作用下从腺癌发展而来，尽管这种转化背后的机制仍存在争议。NEPC 患者的生存率较差，且有效的治疗选择很少。为了改善临床结局，了解调控 NEPC 发生发展的生物学和分子机制至关重要。各种 NEPC 分子驱动因素在 NEPC 发生发展过程中具有时间贡献，尽管可用的治疗方法有限，但目前正在研究几种新型靶向治疗药物。
相似文献
1
Molecular events in neuroendocrine prostate cancer development.神经内分泌前列腺癌发生发展中的分子事件。
Nat Rev Urol. 2021 Oct;18(10):581-596. doi: 10.1038/s41585-021-00490-0. Epub 2021 Jul 21.
2
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.SRRM4 驱动前列腺腺癌在雄激素受体通路抑制下的神经内分泌转化。
Eur Urol. 2017 Jan;71(1):68-78. doi: 10.1016/j.eururo.2016.04.028. Epub 2016 May 11.
3
Molecular model for neuroendocrine prostate cancer progression.神经内分泌前列腺癌进展的分子模型。
BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24.
4
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.神经内分泌前列腺癌的分子特征分析与新药靶标的鉴定。
Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130.
5
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.鉴定治疗相关性神经内分泌前列腺癌的新型诊断生物标志物。
Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021.
6
Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer.神经内分泌前列腺癌的新兴治疗靶点
Curr Oncol Rep. 2025 Apr;27(4):362-374. doi: 10.1007/s11912-025-01643-9. Epub 2025 Feb 27.
7
Understanding the molecular regulators of neuroendocrine prostate cancer.了解神经内分泌前列腺癌的分子调控因子。
Adv Cancer Res. 2024;161:403-429. doi: 10.1016/bs.acr.2024.04.006. Epub 2024 May 31.
8
Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.对一名“N=1”的特殊无反应者进行全面系列分子分析，该患者为转移性前列腺癌，在治疗过程中进展为小细胞癌。
J Hematol Oncol. 2015 Oct 6;8:109. doi: 10.1186/s13045-015-0204-7.
9
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.N-Myc诱导一种由EZH2介导的转录程序驱动神经内分泌前列腺癌。
Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005.
10
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer.靶向组蛋白阅读器ZMYND8可抑制抗雄激素诱导的前列腺癌神经内分泌肿瘤转分化。
Nat Cancer. 2025 Apr;6(4):629-646. doi: 10.1038/s43018-025-00928-z. Epub 2025 Mar 18.
引用本文的文献
1
Proteomic profiling of extracellular vesicles distinguishes prostate cancer molecular subtypes.细胞外囊泡的蛋白质组学分析可区分前列腺癌分子亚型。
bioRxiv. 2025 Aug 2:2025.07.31.667906. doi: 10.1101/2025.07.31.667906.
2
RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation.RNA测序和免疫组织化学联合应用可改善肿瘤生物标志物的解读。
Sci Rep. 2025 Aug 2;15(1):28264. doi: 10.1038/s41598-025-12780-3.
3
New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.神经内分泌前列腺癌潜在治疗靶点的新见解：从实验室到临床
Research (Wash D C). 2025 Jul 31;8:0791. doi: 10.34133/research.0791. eCollection 2025.
4
Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice.前列腺神经内分泌肿瘤分类的重新评估：将分子见解转化为临床实践
Endocr Pathol. 2025 Jul 23;36(1):28. doi: 10.1007/s12022-025-09871-2.
5
Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review).上皮-间质转化（EMT）和干性在前列腺癌神经内分泌分化中的广泛激活及关键作用（综述）
Oncol Rep. 2025 Sep;54(3). doi: 10.3892/or.2025.8942. Epub 2025 Jul 11.
6
High cereblon expression in neuroendocrine cancer confers vulnerability to GSPT1 molecular glue degrader.神经内分泌癌中高表达的 Cereblon 使细胞对 GSPT1 分子胶降解剂敏感。
Exp Hematol Oncol. 2025 Jun 23;14(1):89. doi: 10.1186/s40164-025-00674-z.
7
Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.纵向单细胞分析揭示RUNX1T1是治疗诱导的神经内分泌转分化的早期驱动因素。
bioRxiv. 2025 May 18:2025.05.14.653660. doi: 10.1101/2025.05.14.653660.
8
Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer.生长激素释放激素（GHRH）拮抗剂肽与PI3K亚型抑制剂联合使用可增强前列腺癌细胞死亡。
Cancers (Basel). 2025 May 13;17(10):1643. doi: 10.3390/cancers17101643.
9
A prognostic model for highly aggressive prostate cancer using interpretable machine learning techniques.一种使用可解释机器学习技术的高侵袭性前列腺癌预后模型。
Front Med (Lausanne). 2025 May 12;12:1512870. doi: 10.3389/fmed.2025.1512870. eCollection 2025.
10
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.BRD4抑制剂对神经内分泌前列腺癌肿瘤谱系可塑性的有效治疗靶向作用。
Acta Pharm Sin B. 2025 Mar;15(3):1415-1429. doi: 10.1016/j.apsb.2025.01.007. Epub 2025 Jan 22.
本文引用的文献
1
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.罗伐匹妥珠单抗替西瑞林治疗表达δ样蛋白3的晚期实体瘤的I/II期研究。
NPJ Precis Oncol. 2021 Aug 5;5(1):74. doi: 10.1038/s41698-021-00214-y.
2
Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.前列腺的神经内分泌细胞：组织学、生物学功能及分子机制
Precis Clin Med. 2021 Jan 28;4(1):25-34. doi: 10.1093/pcmedi/pbab003. eCollection 2021 Mar.
3
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.与拓扑替康相比，罗伐匹妥珠单抗替西瑞林作为DLL3高表达小细胞肺癌二线治疗的疗效和安全性：3期TAHOE研究结果
J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Gene regulation by long non-coding RNAs and its biological functions.长非编码 RNA 的基因调控及其生物学功能。
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118. doi: 10.1038/s41580-020-00315-9. Epub 2020 Dec 22.
6
Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.单细胞分析支持人类前列腺癌中腔神经内分泌转化。
Commun Biol. 2020 Dec 16;3(1):778. doi: 10.1038/s42003-020-01476-1.
7
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.AMG 757，一种半衰期延长的、针对 DLL3 的双特异性 T 细胞衔接器，在小细胞肺癌的临床前模型中表现出高效力和高灵敏度。
Clin Cancer Res. 2021 Mar 1;27(5):1526-1537. doi: 10.1158/1078-0432.CCR-20-2845. Epub 2020 Nov 17.
8
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.SWI/SNF 复合物的特异性组成在前列腺癌谱系可塑性中的作用。
Nat Commun. 2020 Nov 3;11(1):5549. doi: 10.1038/s41467-020-19328-1.
9
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.非转移性去势抵抗性前列腺癌和达罗他胺的生存情况。
N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342.
10
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.一种双特异性 DLL3/CD3 IgG 样 T 细胞结合抗体在小细胞肺癌中诱导抗肿瘤反应。
Clin Cancer Res. 2020 Oct 1;26(19):5258-5268. doi: 10.1158/1078-0432.CCR-20-0926. Epub 2020 Jun 18.
Zotero 插件